Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04MBK
|
|||
| Former ID |
DIB010883
|
|||
| Drug Name |
AGS-67E
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1] | |
| Malignant lymphatic [ICD-11: 2A82; ICD-10: C81-C86; ICD-9: 202] | Phase 1 | [1], [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [3] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02175433) A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.